(852) 3426 2888 / (852) 5580 4537
 
 
文章
 
2017-01-06
Review and update of the Hong Kong Epilepsy Guideline on status epilepticus
2017-01-04
多發性硬化症
2015-10-30
三周刊- Lisa 味道 保健專欄 - 救救滑鼠手
2015-10-02
媽咪快報 #1070 - 真假扁平足
2015-09-30
明報週刊2 黑莓拇指
2015-09-30
明報週刊3 腕管綜合症
2015-09-30
明報週刊5 手機肘
2015-09-30
明報週刊6 板機指

Review and update of the Hong Kong Epilepsy Guideline on status epilepticus

Abstract
Convulsive status epilepticus is the most extreme form of seizure. It is a medical and neurological emergency that requires prompt and appropriate treatment. Treatment of convulsive status epilepticus is usually divided into stages/steps. The International League Against Epilepsy has released a new definition of status epilepticus that may help to unify the definition in future studies. Over the last few years new information has become available regarding its management. The Rapid Anticonvulsant Medication Prior to Arrival Trial demonstrated non-inferiority of intramuscular midazolam in early status epilepticus compared with intravenous lorazepam. Valproate and levetiracetam have also emerged as possible alternatives to phenytoin in established status epilepticus. The potential role of lacosamide in this stage of status epilepticus remains to be defined. The ongoing Established Status Epilepticus Treatment Trial may help to determine the most effective treatment for benzodiazepine-resistant status epilepticus. Management of refractory status epilepticus and super-refractory status epilepticus remains mostly non–evidence-based. Increasing recognition of a possible autoimmune aetiology has led to the use of immune-modulation in super-refractory status epilepticus. Ketamine is also increasingly used in this challenging condition. There are also reports of potential use of a ketogenic diet and magnesium.
 

 目前未有中文版本,請看英文版

 

轉載 : http://www.hkmj.org/abstracts/v23n1/67.htm

 

馮斌熙醫生

 
  <<上一頁
1
2
3
4
5
6
7
8
9
10
下一頁>>  
© Copyright 2020 德健醫務所版權所有
Web design by Blue Ocean Lab